Posted by Michael Wonder on 02 Mar 2023
Avadel Pharmaceuticals requests final FDA approval for Lumryz (sodium oxybate) extended-release oral suspension
2 March 2023 - Submitted amendment on 1 March 2023 to the Lumryz new drug application seeking final FDA approval.
Avadel Pharmaceuticals announced today that it has submitted an amendment to the US FDA requesting final approval for Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
